Table 2.

Subgroup analyses of NLR for OS and DFS

Subgroups	Independent cohorts	Sample size	HR* (95% CI) (H/L*)	P value	Study heterogeneity
					χ 2	df*	I 2, %	P value
Overall survival	28	142 64	1.78 (1.49‐2.13)	<0.0001	97.01	27	72	<0.0001
Pathology
Triple‐negative	12	2157	2.18 (1.75‐2.73)	<0.0001	15.70	11	30	0.15
Her2‐positive	6	1094	1.27 (0.94‐1.72)	0.12	8.19	5	39	0.15
Cut‐off value
<3	12	5608	1.79 (1.33‐2.41)	0.0001	47.85	11	77	<0.0001
≥3	16	8656	1.79 (1.42‐2.24)	<0.0001	44.85	15	67	<0.0001
Tumor progression
Early‐stage	16	6984	1.70 (1.33‐2.18)	<0.0001	65.10	15	77	<0.0001
Metastatic	6	768	2.17 (1.68‐2.81)	<0.0001	2.27	5	0	0.81
Geographical region
Asia	18	8180	1.79 (1.42‐2.25)	<0.0001	71.50	17	76	<0.0001
America	3	2897	1.91 (0.83‐4.37)	0.13	9.69	2	79	0.008
Europe	7	3187	1.65 (1.20‐2.27)	0.002	11.94	6	50	0.06
Disease‐free survival	27	115 04	1.60 (1.42‐1.96)	<0.0001
Pathology
Triple‐negative	10	1674	1.77 (1.44‐2.18)	<0.0001	14.40	9	38	0.11
Her2‐positive	5	881	1.41 (1.05‐1.89)	0.02	8.66	4	54	0.07
Cut‐off value
<3	17	7190	1.67 (1.42‐1.96)	<0.0001	34.16	16	53	0.005
≥3	10	4313	1.50 (1.21‐1.86)	0.0003	17.63	9	49	0.04
Geographical region
Asia	18	7817	1.57 (1.34‐1.83)	<0.0001	37.75	17	55	0.003
America	2	257	1.61 (1.09‐2.85)	0.02	0.23	1	0	0.63
Europe	7	3430	1.75 (1.30‐2.35)	0.0002	13.92	6	57	0.03

Abbreviations: CI*, confidence interval; df*, degrees of freedom; HR, Hazard Ratio; H, High group, L, Low group.

The bolds represent summary of subgroup analyses for OS and DFS.